Strados Labs Whitepaper

This whitepaper outlines the limitations of current respiratory diagnostics and highlights how the RESP® Biosensor platform addresses gaps in care through continuous, objective monitoring of lung sounds and chest wall motion. Traditional tools such as spirometry and stethoscope exams are constrained by calibration issues, inter-observer variability, and brief, episodic assessment windows, often leading to delayed or inaccurate diagnosis of conditions like COPD and asthma.

The RESP system, a lightweight wearable sensor, provides 24+ hours of continuous auscultation with noise cancellation, cloud-enabled data integration, and compatibility with clinical workflows. In validation studies, RESP demonstrated significantly greater sensitivity than electronic stethoscopes, detecting more wheezes and coughs in emergency department patients with asthma and COPD. Case studies also show its ability to detect pre-symptomatic changes in lung sounds that preceded hospital readmission, offering opportunities for earlier intervention.

The whitepaper further details how Strados Labs is building the world’s largest clinical-grade bioacoustic dataset to power proprietary AI algorithms, achieving up to 96% accuracy for cough and 94% accuracy for wheeze detection. With applications spanning clinical research, inpatient monitoring, and at-home care, the RESP platform is positioned as a new standard for capturing digital respiratory biomarkers to improve diagnosis, reduce readmissions, and support therapeutic development.